Filing Flows › Health Care › Quest Diagnostics (DGX)

Quest Diagnostics (DGX) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Oct 23, 2026 · Quest Diagnostics (DGX) Q3 2026 earnings results →

Q3 2026 Revenue up 10% year over year to $3.1B · 10¢ of every $1 of revenue kept as net profit · operating margin 15.5%

Quest Diagnostics made $3.1B in Q3 2026 (+10% Y/Y): DIS business $3.0B, All other operating segments $62.0M. Operating margin 15.5%, net earnings $312M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 23, 2026.

Revenue$3.1B

Year over year+10%

Operating margin15.5%

Net earnings$312M

Operating cash flow$611M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $3.1B in Q3 2026, up 10% year over year and up 2% from the previous quarter. DIS business was the largest line at 98% of revenue. DIS business added $0.28B year over year (up 10%), 100% of the total change.

Operating profit was $0.48B, a 15.5% margin (up 1.8 points year over year). Of the extra revenue versus Q3 2025, 33% reached operating profit, above the 14% margin then. Total costs grew 8% against revenue growth of 10%. The fastest-growing cost line was Cost of revenue (+10%). Net earnings were $0.31B, up 27% year over year. The effective tax rate was 23.3%.

Operating cash flow was $0.61B (up 9% year over year), 187% of net income including minority interests. Non-cash charges added back $0.15B of depreciation and amortization and $0.02B of share-based compensation. Working capital and other items added $0.12B. Capital expenditures of $0.17B left free cash flow of $0.45B.

Quarterly history

Quarter	Form	Filed	Revenue	Y/Y	Op. margin	Net earnings	Op. cash flow
Q3 2026	10-Q	Oct 23, 2026	$3.1B	+10%	15.5%	$312M	$611M
Q2 2026	10-Q	Jul 23, 2026	$3.0B	+10%	15.1%	$320M	$597M
Q1 2026	10-Q	Apr 22, 2026	$2.9B	+9%	13.8%	$252M	$278M
Q4 2025	10-K	Feb 26, 2026	$2.8B	+7%	13.8%	$245M	$465M
Q3 2025	10-Q	Oct 21, 2025	$2.8B	+13%	13.7%	$245M	$563M
Q2 2025	10-Q	Jul 23, 2025	$2.8B	+15%	15.9%	$282M	$544M
Q1 2025	10-Q	Apr 23, 2025	$2.7B	+12%	13.0%	$220M	$314M

Charts

Latest (Q3 2026): Y/Y +10%, Q/Q +2%.

From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.

Latest (Q3 2026): Net income $326M, Operating cash flow $611M.

-16.9% since FY2020: buybacks shrank the count.

Cash $420M, short-term investments —, long-term debt $5.7B at 2025-12-31.

Services-Medical Laboratories; dot size is quarterly revenue; dashed lines are the industry's medians.